
Poolbeg Pharma plc - Agreement signed for MelioVac with University College Dublin
POLB Mon, 06 Dec 2021, 07:05 GMT
Jeremy Skillington, CEO of Poolbeg Pharma and Cathal Friel tell us about the recently signed option agreement with University College Dublin for a Melioidosis Vaccine candidate, MelioVac, and a licence to evaluate 5 other infectious disease portfolio assets.

Cathal Friel
Chairman
Jeremy Skillington
Chief Executive Officer
Management Team, Poolbeg Pharma
Wed, 3 Jan 2024, 11:00am GMT
Jeremy Skillington, Chief Executive Officer
Wed, 30 Nov 2022, 10:00am GMT
Jeremy Skillington, Chief Executive Officer
Mon, 5 Sep 2022, 11:00pm BST
Cathal Friel, Chairman
Wed, 27 Apr 2022, 12:00pm BST
Jeremy Skillington, Chief Executive Officer
Thu, 14 Apr 2022, 5:00pm BST
Jeremy Skillington, Chief Executive Officer
Fri, 1 Apr 2022, 7:05am BST
Jeremy Skillington, Chief Executive Officer
Fri, 25 Mar 2022, 7:05am GMT
Management Team, Poolbeg Pharma
Thu, 3 Mar 2022, 9:00am GMT
Liam Tremble, PhD, Project Manager
Thu, 24 Feb 2022, 7:05am GMT
Jeremy Skillington, Chief Executive Officer
Mon, 31 Jan 2022, 7:05am GMT
Cathal Friel, Chairman
Mon, 6 Dec 2021, 7:05am GMT
Elaine Sullivan, Poolbeg Scientific Advisory Board
Wed, 1 Dec 2021, 7:00am GMT
Cathal Friel, Chairman
Thu, 18 Nov 2021, 5:11pm GMT
Jeremy Skillington, Chief Executive Officer
Tue, 20 Jul 2021, 9:00am BST